23948sdkhjf

Biovitrum sells UK part

Biovitrum will soon spin-out a British subsidary
The Swedish biopharmaceutical company Biovitrum has announced the initiation of a process aiming to spin out its small molecule UK based R&D subsidiary Cambridge Biotechnology, as well as a range of primary care projects.

According to Biovitrum, this proposed transaction reflects its previously announced decision to focus its in-house R&D on specialist pharmaceuticals and protein therapeutics. Biovitrum has engaged Nomura Code in this process.

The Cambridge Biotechnology R&D pipeline includes one phase II neuropathic pain project; one phase II and one phase I obesity projects as well as a highly novel leptin mimetic candidate drug in obesity; and one pre-clinical and four pain and inflammation discovery programmes.
Kommentera en artikel
Meddela redaktionen
Medlemsnytt
Se alla medlemsnyheter
Mest läst
Senaste nytt
Se senaste nytt
Utvalda artiklar
Utvalda nyheter från förstasidan
Fritt fram sprida desinformation om covid-19 på Twitter
Outsourcing som strategi för ökad trovärdighet
Roche lägger ner utveckling av Alzheimerbehandling
Viss effekt av Alzheimers-behandling bekräftas i studie – Bioarctic stiger på börsen
Astra Zeneca köper immunterapibolaget Neogene i miljardaffär
Svensk export av läkemedel ökar kraftigt
Andra Nordiska Medier
Rent
MedTech Magazine
Recycling

Sänd till en kollega

0.094